Anixa Biosciences president, COO, & CFO buys $15,620 in shares

Michael Catelani, President, Chief Operating Officer, and Chief Financial Officer of Anixa Biosciences Inc. (NASDAQ:ANIX), acquired common stock totaling $15,620 on September 30, 2026.

Mr. Catelani purchased 5,500 shares of Anixa Biosciences common stock at a price of $2.84 per share. Following this transaction, Mr. Catelani directly holds 50,000 shares of the company’s common stock. The stock has since climbed to $2.99, delivering a 12% return over the past week. According to InvestingPro analysis, which indicates the stock appears overvalued at current levels, the biotechnology company holds more cash than debt on its balance sheet. InvestingPro offers 7 additional exclusive tips for ANIX investors.

In other recent news, Anixa Biosciences announced significant developments in its clinical and patent endeavors. The company reported that a patient in its Phase 1 trial for lira-cel, a CAR-T therapy targeting recurrent ovarian cancer, exhibited stable disease 90 days post-treatment. This marks the first such response in Anixa’s CAR-T cell therapy trial. Additionally, Anixa received a composition-of-matter patent from IP Australia for its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic and offers protection in Australia through 2040.

In response to these developments, H.C. Wainwright reiterated a Buy rating on Anixa’s stock, though it adjusted the price target from $7 to $6. The firm cited the recent patent issuance as a reason for the target adjustment while maintaining confidence in the company’s prospects. These updates reflect Anixa’s ongoing efforts in the fields of cancer treatment and prevention.